Hormonal
Administration of a novel probiotic formulation (WBF-011) containing Akkermansia muciniphila, Anaerobutyricum hallii, Clostridium beijerinckii, Clostridium butyricum, and Bifidobacterium infantis significantly improves postprandial glucose control in subjects with type 2 diabetes.
If you have Type 2 Diabetes, adding a specific probiotic formulation (WBF-011) containing five specific anaerobic bacteria and inulin, taken twice daily with meals for 12 weeks, may help lower your post-meal blood sugar spikes and slightly improve your long-term A1c levels. This intervention was shown to be safe and well-tolerated in a clinical trial, suggesting it could be a useful adjunct to your current diabetes management plan, especially if you are already on metformin.
Compared with placebo, a statistically significant decrease in total glucose AUC0-180 min was observed in WBF-011 group (−36.1 mg/dL/180 min; p=0.0500)... Incremental glucose AUC0-180 min was also lower in WBF-011 group (−28.56 mg/dL/180 min; p=0.0066)... The validated measure of long-term glucose control, A1c, was reduced by 0.6 compared with placebo (p=0.0540)
Why this rating
Randomized, double-blind, placebo-controlled trial, but with a small sample size (n=76) and short duration (12 weeks).
Source
Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation
Fanny Perraudeau et al. · BMJ Open Diabetes Research & Care · 2020
DOI 10.1136/bmjdrc-2020-001319
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →